This invention relates to compounds of formula (I), ##STR1## pharmaceutically acceptable salt thereof, and pharmaceutically acceptable solvates of either entity, wherein X is CH or N; Y is optionally monousaturated C.sub.3 -C.sub.5 alkylene optionally substituted with C.sub.1 -C.sub.4 alkyl or methylene; R.sup.1 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or C.sub.3 -C.sub.6 alkenyl; R.sup.2 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or CONR.sup.5 R.sup.6 ; R.sup.3 and R.sup.4 are each independently selected from H; C.sub.1 -C.sub.4 alkyl optionally substituted with NR.sup.5 R.sup.6 ; C.sub.1 -C.sub.4 alkoxy; halo; CONR.sup.5 R.sup.6 and aryl; R.sup.5 and R.sup.6 are each independently selected from H and C.sub.1 -C.sub.4 alkyl; and m and n are each independently 1, 2 or 3; are potent and selective thrombin inhibitors useful in the treatment of, inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.
本发明涉及式(I)的化合物,其中X为CH或N;Y为可选择的单不饱和C.sub.3-C.sub.5烷基,可选择地取代为C.sub.1-C.sub.4烷基或亚甲基;R.sup.1为H;C.sub.1-C.sub.4烷基,可选择地取代为C.sub.1-C.sub.4烷氧基,OH,NR.sup.5R.sup.6,CONR.sup.5R.sup.6,C.sub.3-C.sub.6环烷基或芳基;或C.sub.3-C.sub.6烯基;R.sup.2为H;C.sub.1-C.sub.4烷基,可选择地取代为C.sub.1-C.sub.4烷氧基,OH,NR.sup.5R.sup.6,CONR.sup.5R.sup.6,C.sub.3-C.sub.6环烷基或芳基;或CONR.sup.5R.sup.6;R.sup.3和R.sup.4各自独立地选自H;C.sub.1-C.sub.4烷基,可选择地取代为NR.sup.5R.sup.6;C.sub.1-C.sub.4烷氧基;卤素;CONR.sup.5R.sup.6和芳基;R.sup.5和R.sup.6各自独立地选自H和C.sub.1-C.sub.4烷基;m和n各自独立地为1、2或3;这些化合物是有效且选择性的凝血酶
抑制剂,可用于治疗深静脉血栓形成等疾病。